Keywords: lilly, cell, pathways, evaluate, aptosyn, plus, gemzar

Lilly and Cell Pathways to evaluate Aptosyn plus Gemzar

Article | 02 March 2000

Print This

Cell Pathways, in collaboration with Eli Lilly, is to fund clinicaltrials to investigate the potential of the former's Aptosyn (exisulind) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in